The steroid resistance of Crohn's disease

Journal of Investigative Medicine

Volumn 47, Issue 6, 1999, Pages 319-325

  Mingrone, Geltrude ^a   DeGaetano, Andrea ^b   Pugeat, Michel ^c   Capristo, Esmeralda ^a   Greco, Aldo V ^a   Gasbarrini, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b CNR   (Italy)

^c Hopital de l'Antiquaille   (France)

Author keywords

Binding analysis corticosteroid binding globulin; Euglycemic hyperinsulinemic clamp; Indirect calorimetry; Nonlinear mixed effects model

Indexed keywords

GLUCOCORTICOID; GLUCOSE; HYDROCORTISONE; PREDNISOLONE; SERUM ALBUMIN; TRANSCORTIN;

ADULT; ARTICLE; BINDING SITE; BLOOD; CROHN DISEASE; DRUG RESISTANCE; HUMAN; ILEITIS; INSULIN RESISTANCE; MALE; METABOLISM; PHYSIOLOGY;

ADULT; BINDING SITES; CROHN DISEASE; DRUG RESISTANCE; GLUCOCORTICOIDS; GLUCOSE; HUMANS; HYDROCORTISONE; ILEITIS; INSULIN RESISTANCE; MALE; PREDNISOLONE; SERUM ALBUMIN; TRANSCORTIN;

EID: 0033160422     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Murch SH, Walker-Smith JA. Medical management of inflammatory bowel disease. Ball Clin Gastroenterol 1994;8:133-48.
2. Friedmann M, Strang LB. Effect of long-term corticosteroids and corticotropin on the growth of children. Lancet 1966;ii:568-9.
3. Bouhnik Y, Lemann MJY, Scemama G, Tai R, Matuchansky C. Long term follow-up of patients with Crohn's disease treated with azathioprine or 6-Mercaptopurine. Lancet 1996;347:215-9.
4. Löfberg R. Medical treatment for inflammatory bowel disease-refinements and new modalities. J Internal Med 1997;241:1-4.
5. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M, Hanauer SB, McDonald JWD for the North American Crohn's Study Group Investigators. Metothrexate for the treatment of Crohn's disease. N Engl J Med 1995;332:292-7.
6. Barnes P.J, Greening AP, Crompton GK. Glucocorticoid resistance in asthma. Am J Respir Crit Care Med 1995;152:S125-42.
7. Kirkham B, Corkill MM, Davison SC, Panayi GS. Response to glucocorticoid treatment in rheumatoid arthritis: in vitro cell mediated immune assays predict in vivo response. J Rheumatol 1991;18:1130-3.
8. Langhoff E., Laderfoged J, Jacobbsen BK. Recipient lymphocyte sensitivity to methyl prednisolone affects cadaver kidney graft survival. Lancet 1986;ii:1296-7.
9. Norbato G, Bevilacqua M, Vago T. Cortisol resistance in acquired immune deficiency syndrome. J Clin Endocrinol Metab 1992;74:608-13.
10. Quan SF, Sedwick JB, Nelson MV, Busse AW. Corticosteroid resistance in eosinophilia gastritis: relation to in vitro eosinophil survival and interleukin 5. Ann Allergy 1993;70:256-60.
11. Lichtiger S, Present DH, Kornblum A, Gelernt I, Bauer J, Galler G. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
12. Goulding NJ, Guyre PM. Glucocorticoids and the immune response. Curr Opin Immunol 1993;5:108-13.
13. Davies G, Evans CM, Shand WS, Walker-Smith JA. Surgery for Crohn's disease: influence of site of disease and operative procedure on outcome. Br J Surg 1990;77:81-94.
14. Ray DW. Molecular mechanisms of glucocorticoid resistance. J Endocrinol 1996;149:1-5.
15. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease study. Gastroenterology 1976;70:439-44.
16. Bonora E, Del Prato S, Bonadonna RC, Gulli G, Solini A, Shank ML, Ghiatas AA, Lancaster JL, Kilcoyne RF, Alyassin AM, DeFronzo RA. Total body fat content and fat topography are associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women. Diabetes 1992;41:1151-9.
17. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;273:E214-23.
18. Ferrannini E., Barrett E, Bevilacqua S. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983;72:1737-47.
19. Mingrone G, DeGaetano A, Greco AV, Capristo E, Benedetti G, Castagneto M, Gasbarrini G. Reversibility of insulin resistance in obese diabetic patients: role of plasma lipids. Diabetologia 1997;40:599-605.
20. Petrides AS, Groop LC, Riely CA, DeFronzo RA. Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis. J Clin Invest 1991;88:561-70.
21. Ferrannini E. The theoretical basis of indirect calorimetry: a review. Metabolism 1988;3:287-301.
22. Heyns W, VanBaelen H, De Moor P. Study of steroid protein binding by means of competitive adsorption: application to cortisol binding in plasma. Clin Chim Acta 1967;18:361-70.
23. Pugeat M, Chrousos GP, Nisula BC, Loriaux DL, Brandon D, Lipsett MB. Plasma cortisol transport and primate evolution. Endocrinology 1984;115:357-61.
24. Pugeat M, Bonneton A, Perrot D, Rocle-Nicolas B, Lejeune H, Grenot C, Déchaud H, Brébant C, Motin J, Cuilleron CJ. Decreased immunoreactivity and binding activity of corticosteroid-binding globulin in serum in septic shock. Clin Chem 1989;35:1675-9.
25. Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL. Low serum testosterone and sex hormone-binding globulin in massively obese men. J Clin Endocrinol Metab 1977;45:1211-9.
26. Ashbrook JD, Spector AA, Fletcher JB. Medium-chain fatty acid binding to human plasma albumin. J Biol Chem 1972;247:7038-42.
27. Bertuzzi A, Finotti E, Mingrone G, Greco AV. Sebacic binding to human plasma albumin. Biochem Pharmacol 1993;45:697-702.
28. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1983;11:303-19.
29. Sheiner LB, Beal SL. Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokinet Biopharm 1985;13:185-201.
30. De Gaetano A, Mingrone G, Greco AV, Castagneto M. NON-MEM improves group parameter estimation for the minimal model of glucose kinetics. Am J Physiol 1996;34:E932-7.
31. Press WH, Flannery BP, Teukolsky SA, Vetterling WT. Numerical recipes in C. The art of scientific computing. Cambridge, MA: Cambridge University Press, 1994;384.
32. Mingrone G, Greco AV, Benedetti G, Capristo E, Semeraro R, Zoli G, Gasbarrini G. Increased resting lipid oxidation in Crohn's disease. Dig Dis Sci 1996;41:72-6.
33. McMahon M, Gerich J, Rizza R. Effect of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev 1988;4;17-30.
34. Ferrannini E, Vichi S, Beck-Nielsen H, Laakso M, Paolisso G, Smith U. Insulin action and age. Diabetes 1996;45:947-53.
35. Goulding NJ, Godolphin JL, Sharlard PR, Peers SH, Sampson M, Maddison PJ, Flower RJ. Anti-inflammatory lipocortin-I production by peripheral blood leucocytes in response to hydrocortisone. Lancet 1990;335:1416-8.
36. Goulding NJ, Podgorski MR, Hall ND, Flower RJ, Browning JL, Pepinsky RB, Maddison PJ. Autoantibodies to recombinant lipocortin-1 in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 1989;48:843-50.
37. Stevens TRJ, Smith SF, Rampton DS. Antibodies to human recombinant lipocortin-I in inflammatory bowel disease. Clin Sci 1993;84:381-6.
38. Beattie RM, Goulding NJ, Walker-Smith JA, MacDonald TT. Lipocortin-1 autoantibody concentration in children with inflammatory bowel disease. Aliment Pharmacol Ther 1995;9:541-5.
39. Hurley DM, Accili D, Stratakis CA. Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin Invest 1990;87:680-6.
40. McDermott P, Malchoff DM, Brufsky A, Javier E, Readon G, Malchoff CD. A mutation of the human glucocorticoid receptor may cause primary cortisol resistance. Proc 73rd Meeting of the Endocrine Soc 1991;1381.
41. Mingrone G, Benedetti G, Capristo E, De Gaetano A, Greco AV, Tataranni PA, Gasbarrini G. Twenty-four-hour energy balance in Crohn's patients: metabolic implications of steroid treatment. Am J Clin Nutr 1997;67:118-23.
42. Kragh-Hansen U. Structure and ligand binding properties of human serum albumin. Dan Med Bull 1990;35:57-84.
43. Pugeat M, Dunn JF, Nisula BC. Transport of steroid hormones: interaction of 70 drugs with testosterone-binding and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981;53:69-75.
44. Tait JF, Tait SAS. The effect of plasma protein binding on the metabolism of steroid hormones. J Endocrinol 1991;131:339-57.
45. 1-13C)leucine. Kidney Int 1992;41:132-8.
46. Iranmanesh A, Lizarralde G, Johnson ML, Veldhuis JD. Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. J Clin Endocrinol Metab 1990;70:155-61.